Naoaki Kato - Suzuken Executive Officer, Director of Tokyo Central Sales
Director
Naoaki Kato is Executive Officer, Director of Tokyo Central Sales of Suzuken Co
Phone | 81 52 961 2331 |
Web | https://www.suzuken.co.jp |
Suzuken Management Efficiency
The company has return on total asset (ROA) of 0.0132 % which means that it generated a profit of $0.0132 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0378 %, meaning that it generated $0.0378 on every $100 dollars invested by stockholders. Suzuken's management efficiency ratios could be used to measure how well Suzuken manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Jane Warner | RBC Bearings Incorporated | 72 | |
George Corbin | Edgewell Personal Care | 56 | |
Henry Knueppel | RBC Bearings Incorporated | 68 | |
Kadri Dagdelen | Barrick Gold Corp | 60 | |
Safiatou BaNDaw | Barrick Gold Corp | 64 | |
Robert Prichard | Barrick Gold Corp | 68 | |
Michael Hilton | RBC Bearings Incorporated | 65 | |
Pablo Marcet | Barrick Gold Corp | 53 | |
Curtis Stoelting | RBC Bearings Incorporated | 60 | |
David Hoover | Edgewell Personal Care | 72 | |
Karl Voltaire | Barrick Gold Corp | 63 | |
Cory Nettles | Weyco Group | 48 | |
Gary Waring | Edgewell Personal Care | 61 | |
Rakesh Sachdev | Edgewell Personal Care | 64 | |
Tina Chang | Weyco Group | 45 | |
Jemaluddin Kassum | Barrick Gold Corp | 68 | |
James Johnson | Edgewell Personal Care | 68 | |
Anthony Munk | Barrick Gold Corp | 57 | |
Andrew Quinn | Barrick Gold Corp | 66 | |
Stephen Burt | RBC Bearings Incorporated | 55 | |
Jan Bertsch | RBC Bearings Incorporated | 64 |
Management Performance
Return On Equity | 0.0378 | |||
Return On Asset | 0.0132 |
Suzuken Leadership Team
Elected by the shareholders, the Suzuken's board of directors comprises two types of representatives: Suzuken inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Suzuken. The board's role is to monitor Suzuken's management team and ensure that shareholders' interests are well served. Suzuken's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Suzuken's outside directors are responsible for providing unbiased perspectives on the board's policies.
Masayuki Tanaka, Executive Officer, Director of Sales Planning | ||
Keiji Yoza, Managing Executive Officer, Director of Medicine | ||
Nobuo Suzuki, Senior Managing Executive Officer, Chief Director of Business, Director | ||
Hiromi Miyata, Senior Managing Executive Officer, Director of Business Planning, Director | ||
Shigeru Asano, Managing Executive Officer, Chief Director of SCM | ||
Masanobu Nohara, Executive Officer, Chief Director of Administration | ||
Yoshiaki Yagioka, Managing Executive Officer, Director of Hospital | ||
Mitsuru Sato, Executive Officer, Director of Diagnostic Medicine | ||
Wakatsu Shinke, Executive Officer, Director of Aiseikan Sales | ||
Keisuke Ueda, Independent Director | ||
Toshiaki Iwatani, Independent Director | ||
Akihiko Someya, Executive Officer, Director of Saitama Sales | ||
Hiroshi Ohta, Executive President Representative Director | ||
Masao Saito, Executive Officer, Director of Tokyo Hospital Sales | ||
Takeshi Nakahara, Executive Officer, Senior Director of Hospital | ||
Hisashi Tamura, Executive Officer, Director of Mie Sales | ||
Naoaki Kato, Executive Officer, Director of Tokyo Central Sales | ||
Norio Kosakai, Director of Accounting | ||
Chie Takahashi, Ex Office | ||
Takashi Kamitani, Executive Officer, Director of Business Planning | ||
Hirofumi Tanaka, Executive Officer, Chief Director of SCM | ||
Osamu Abe, Executive Officer, Director of Human Resources Development | ||
Yoshiki Bessho, Chairman of the Executive Board, Representative Director | ||
Yoshimichi Izawa, Executive Officer, Senior Director of Health Insurance Pharmacy | ||
Naoyuki Sugihara, Executive Officer, Deputy Director of Business Planning | ||
Tadashi Yamamoto, Executive Officer, Director of Human Resources Development | ||
Toru Yoshida, Managing Executive Officer, Director of Nagoya Sales | ||
Fumito Honzawa, Executive Officer |
Suzuken Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Suzuken a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0378 | |||
Return On Asset | 0.0132 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.01 % | |||
Current Valuation | 693.82 M | |||
Shares Outstanding | 87.94 M | |||
Shares Owned By Insiders | 23.58 % | |||
Shares Owned By Institutions | 29.62 % | |||
Price To Earning | 19.42 X | |||
Price To Book | 0.68 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Suzuken in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Suzuken's short interest history, or implied volatility extrapolated from Suzuken options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Suzuken Pink Sheet
If you are still planning to invest in Suzuken check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Suzuken's history and understand the potential risks before investing.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
CEOs Directory Screen CEOs from public companies around the world | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Fundamental Analysis View fundamental data based on most recent published financial statements |